newsfilter
← Earnings
Earnings Releases·

Illumina — Q3 2026 Earnings Summary

  • Q3 2026 revenue reached $1.13 billion (up 4.2% YoY), with GAAP diluted EPS rising to $1.43 from $0.98 and non-GAAP diluted EPS increasing to $1.62 from $1.34.
  • Full-year fiscal 2026 guidance was raised across the board: total revenue to $4.64–$4.66 billion, non-GAAP operating margin to 23.6%, and non-GAAP diluted EPS to $5.40–$5.45.
  • Strong performance was driven by healthy clinical demand and robust NovaSeq X placements, resulting in free cash flow of $378 million and a cash position of $1.34 billion.
  • Management cited optimism regarding AI's role in transforming human biology, though the company faces ongoing risks related to China's Unreliable Entities List, tariff uncertainties, and potential litigation from prior acquisitions.
Company
ILLUMINA INC
Sector
Healthcare
Industry
Diagnostics & Research